A range of patient, medical groups and pharmaceutical companies are confirmed to appear before Monday's public hearing of the Senate inquiry into access to new cancer medicines.
The hearing will be dominated by an extraordinary collection of patient groups.
Ovarian Cancer Australia, Australian Melanoma Research Foundation, Leukaemia Foundation of Australia, Cure Brain Cancer Foundation, CanTeen, The Kids’ Cancer Project, Rare Cancers Australia, The Unicorn Foundation, Palliative Care Australia, Melanoma Patients Australia, Advanced Prostate Cancer Support Group, Australian Melanoma Consumer Alliance and Breast Cancer Network Australia, will all appear.
The Cancer Drugs Alliance, which is a cross-section of stakeholder groups, including clinicians, patient support groups and pharmaceutical companies, will also appear.
Australian and New Zealand Children's Haematology Oncology Group, Society of Hospital Pharmacists of Australia, Private Cancer Physicians of Australia Limited and Clinical Oncology Society of Australia, will represent healthcare professionals.
Industry will be represented by Medicines Australia and a number of companies, including MSD, Novartis and Roche.
The Department of Health confirmed late Thursday that its officials will appear at the hearing, along with yet to be confirmed members of the Pharmaceutical Benefits Advisory Committee.
